Vector Velocity Imaging in AAA Patients
Key facts
- Who runs it
- St. Olavs Hospital
- Where
- Norway1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 14 people enrolled
- Started
- 1 Apr 2023
- Expected to end
- 31 Dec 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- Vector flow imaging measurement
- Record updated
- 21 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (12)Hide the full registry criteria
Who can take part
- Diagnosed with AAA
- AAA diameter below treatment threshold of 5.5 cm
Who cannot take part
- Hypersensitivity to the active substance(s) or any of the excipients in Sonovue
- Right-to-left cardiac shunt
- Severe pulmonary hypertension (pulmonary artery pressure > 90mmHg)
- Uncontrolled systemic hypertension
- Severe pulmonary disease (e.g. COPD GOLD 3 or 4, adult respiratory distress syndrome)
- Clinically unstable cardiac disease (recent, < 3 months, or ongoing myocardial infarction, unstable angina at rest, recent percutaneous coronary intervention, clinically worsening cardiac symptoms, severe cardiac arrhythmia's, endocarditis, etc.)
- End-stage liver disease
- Loss of renal function (GFR < 31 ml/min), end-stage renal disease
- Prosthetic valves
- Sepsis
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this observational study is to perform an in vivo feasibility study using real time (3D) ultrasound based vector flow imaging in 10 AAA patients (5 with intraluminal thrombus and 5 without intraluminal thrombus). Furthermore, the investigators will investigate the added value of contrast microbubbles in these high framerate, plane wave ultrasound measurements.
Read full original descriptionShow less
Included patients will undergo ultrasound scanning of their AAA, using multiple ultrasound sequences. Sequences will be tested with and without the addition of ultrasound contrast microbubbles.
The 2 groups in the trial
- AAA patients, without intraluminal thrombus
patients diagnosed with an abdominal aneurysm, with a diameter below the treatment threshold of 5.5 cm and without intraluminal thrombus.
Treatment: Vector flow imaging measurement
- AAA patients, with intraluminal thrombus
patients diagnosed with an abdominal aneurysm, with a diameter below the treatment threshold of 5.5 cm and with intraluminal thrombus.
Treatment: Vector flow imaging measurement
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Thrombus Formation Prediction in Abdominal Aneurysms Using Vector Flow Imaging
- Record updated
- 21 July 2026